COST-EFFECTIVENESS AND COST-UTILITY OF GENOTHERAPEUTIC DRUG NEOVASCULGEN IN TREATMENT OF CHRONIC LOWER LIMB ISCHEMIA

• Main Authors: S. L. Plavinsky, P. I. Shabalkin
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2017-11-01
• Series: Медицинский совет
• Subjects: cost-effectiveness analysis; cost-utility analysis; chronic lower limb ischemia; neovasculgen
• Online Access: https://www.med-sovet.pro/jour/article/view/2179

Pl-VEGF165 (Neovasculgen) is a new genotherapeutic drug for treatment of chronic lower limb ischemia.  It is registered in Russia and underwent effectiveness assessment in clinical trial. Objective of this study is to report results of the economical modeling study to compare long-term effectiveness and costs of the treatment. The comparison show that the treatment with this drug allows to decrease number of amputations by 6.5 fold and increase quality adjusted length of life by 2.6 QALYs. Summary  costs were lower with new drug by 574 thousand rubles with lifelong modeling and by 353 thousand rubles in first 5 years.